Results 31 to 40 of about 8,127 (167)

Investigating the hepato-protective properties of chamomile oil and olive leaves extracts against ribociclib-induced hepatotoxicity [PDF]

Brazilian Journal of Biology
A new approach to overcome or reduce these toxicities is by using antioxidants. Ribociclib, a CDK4/6 inhibitor used in the treatment of breast cancer, has been linked to hepatotoxicity and may contribute to the development of Hepatocellular carcinoma in ...
A. A. Alsarhan, A. S. Khwaldeh, J. D. Al-Shawabkeh, A. A Shoiab, R. Al-Shdefat, S. Al-Fawaeir, I. Yousef   +6 more
doaj   +1 more source

DataSheet_1_Case Report: Ribociclib-induced phototoxicity presented as dyschromia with subsequent bullae formation.docx

, 2023
Ribociclib, a cyclin-dependent kinase 4/6 inhibitor, is a novel targeted therapy for advanced-stage breast cancer. Although ribociclib-induced cutaneous side effects have been previously noted, they have not been well documented.
Chiu-Hsuan Cheng, Chung-Hsing Chang, Sung-Chao Chu (9921936), Chiu-Hsuan Cheng (16874931), Jyun-Yan Jhan (16874925), Wei-En Wang (16874928), Chung-Hsing Chang (3145977), Sung-Chao Chu, Jyun-Yan Jhan, Wei-En Wang   +9 more
core   +1 more source

In Vivo pharmacokinetic interactions of ribociclib with rivaroxaban and apixaban in rats: implications for increased drug exposure and dose adjustments

Frontiers in Pharmacology
BackgroundApixaban (API) and rivaroxaban (RIVA) are orally available inhibitors of coagulation factor Xa and are commonly used to treat cancer-related venous thrombosis.
Zihan Liu, Zihan Liu, Wenyu Du, Wenyu Du, Qimin Wang, Zhi Wang, Jing An, Yinling Ma, Zhanjun Dong, Ying Li   +9 more
doaj   +1 more source

Maternal and Neonatal Complications Associated with Breast Cancer Systemic Treatments—A VigiBase Disproportionality Analysis Study

Clinical Pharmacology &Therapeutics, EarlyView.
Pregnancy‐associated breast cancer (PrBC) presents therapeutic challenges. Understanding maternal–fetal safety of systemic anticancer therapies is critical. We performed a case/non‐case disproportionality analysis using the WHO global pharmacovigilance database up to January 2024, to evaluate maternal–fetal outcomes associated with breast cancer (BC ...
Rayan Kabirian, Floriane Jochum, Elise Dumas, Florence Coussy, Kevin Bihan, Bénédicte Lebrun‐Vignes, Barbara Pistilli, Marc‐Antoine Benderra, Lise Selleret, Laurent Chouchana, Fabien Reyal, Anne‐Sophie Hamy, Paul Gougis   +12 more
wiley   +1 more source

An integrated assessment of the ADME properties of the CDK4/6 Inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data

Pharmacology Research & Perspectives, 2020
Ribociclib (LEE011, Kisqali ®) is a highly selective small molecule inhibitor of cyclin‐dependent kinases 4 and 6 (CDK4/6), which has been approved for the treatment of advanced or metastatic breast cancer.
Alexander D. James, Hilmar Schiller, Cyrille Marvalin, Yi Jin, Hubert Borell, Ad F. Roffel, Ulrike Glaenzel, Yan Ji, Gian Camenisch   +8 more
doaj   +1 more source

LEM4 interacts with β-catenin and promotes β-catenin-dependent transcription activity to confers ribociclib resistance in breast cancer cells

Scientific Reports
Background Ribociclib, a CDK4/6 inhibitor, is a targeted therapy for breast cancer management. However, acquired resistance to ribociclib is a common clinical challenge.
Qi Tang, Xintong Zhao, Hui Li, Jiaqian Liao, Bingyu Ouyang, Chunxiao Ma, Dedian Chen   +6 more
doaj   +1 more source

Palbociclib in the Treatment of HR+/ HER2‐ Advanced or Metastatic Breast Cancer in Australia: A Real‐World Retrospective Analysis

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This study investigated the real‐world use of CDK4/6 inhibitors in Australian patients with HR+/HER2‐ advanced or metastatic breast cancer, providing data on patient demographics, treatment patterns, and outcomes with palbociclib. ABSTRACT Background There is limited real‐world data on the use of CDK4/6 inhibitors in Australian patients with HR+/HER2 ...
Louise Nott, Eugene Moylan, Maree Colosimo, Giles Stratton, Thomas Chiu, Mahsa H. Kouhkamari, Maureen Hitschfeld, Jessica Michie, Richard De Boer   +8 more
wiley   +1 more source

A comparative analysis of Palbociclib and Ribociclib in metastatic hormone receptor-positive, HER2-negative breast cancer: a prospective mid term follow-Up study from an Indian cohort

BMC Cancer
Introduction Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, such as Palbociclib and Ribociclib, have significantly improved outcomes for patients with hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer. Although clinical trials
Nihanthy D. Sreenath, Suresh Pandalanghat, Amul Kapoor, Rajath Govind, M. R. Kaushik, Rajesh Nair, Dipen Bhuva, Anvesh Rathore, Manish Kumar, Deepak Mulajker   +9 more
doaj   +1 more source

Systemic Therapy Management Strategies for Early‐Stage Breast Cancer in Australia

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Advances in systemic therapy for early‐stage breast cancer in Australia highlight genomic‐guided decisions, subtype‐specific strategies, and emerging targeted and immunotherapies, shaping personalized and de‐escalated treatment approaches. ABSTRACT Breast cancer is the most common cancer among Australian women, with early‐stage disease (Stages I, II ...
Nicholas Zdenkowski, Rachel Dear, Sanjeev Kumar, Hilary Martin, Dhanusha Sabanathan, Stephen J. Luen, Belinda Yeo   +6 more
wiley   +1 more source

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

, 2019
BACKGROUND: In an earlier analysis of this phase 3 trial, ribociclib plus fulvestrant showed a greater benefit with regard to progression-free survival than fulvestrant alone in postmenopausal patients with hormone-receptor-positive, human epidermal ...
Beck J. T., Sondhi M., Jerusalem G., Chakravartty, Arunava, Sonke, Gabe S., Nusch A., De La Cruz-Merino L., Esteva, Francisco J, Rodriguez-Lorenc, Karen, Esteva F. J., Sonke, Gabe S, Esteva, Francisco J., Sonke G. S., Slamon, Dennis J., Bianchi G. V., Sondhi, Manu, Wang Y., Im S. -A., Beck, J Thaddeus, Martin, Miguel, Neven P., Chakravartty A., Nusch, Arnd, De Laurentiis M., Bianchi, Giulia V., De Laurentiis, Michelino, Jerusalem, Guy, Petrakova K., Rodriguez-Lorenc K., Bianchi, Giulia V, De la Cruz-Merino, Luis, Beck, J. Thaddeus, Fasching, Peter A, Slamon, Dennis J, Pivot X., Chia, Stephen, Neven, Patrick, Fasching, Peter A., Chia S., Petrakova, Katarina, Taran, Tetiana, Slamon D. J., Pivot, Xavier, Taran T., Martin M., Im, Seock-Ah, Wang, Yingbo, Fasching P. A.   +47 more
core   +1 more source